A carregar...
Combination of cetuximab and PP242 synergistically suppress the progression of wild-type KRAS colorectal carcinoma
Mammalian target of rapamycin (mTOR) has been shown to be overactive in human colorectal cancer, but the first-generation mTOR inhibitor, rapamycin, has failed to show clinical efficacy against colorectal cancer. On the other hand, although the second-generation mTOR inhibitor, PP242, has exerted su...
Na minha lista:
| Publicado no: | Onco Targets Ther |
|---|---|
| Main Authors: | , , , , , , , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
Dove Medical Press
2015
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4636092/ https://ncbi.nlm.nih.gov/pubmed/26586952 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2147/OTT.S82453 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|